Belite Bio: The Picture Is Still Unclear
Belite Bio is a biotech firm specializing in innovative therapies for retinal degenerative eye diseases with high unmet needs ...
Belite Bio Announces Registered Direct Offering of $15 Million
Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage biopharmaceutical drug development company focused ...
Belite Bio to sell 258,309 shares at $58.07 in registered direct offering
Belite Bio (BLTE) announced that it has entered into a securities purchase agreement with a new, fundamental healthcare investor for the ...
Business Insider4 天
Belite Bio Announces Registered Direct Offering of $15 Million
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel ...
Nasdaq4 天
Belite Bio, Inc. Announces $15 Million Registered Direct Offering of American Depositary Shares
Belite Bio, Inc. has announced a securities purchase agreement with a new healthcare investor to sell 258,309 American Depositary Shares (ADSs) and warrants at a price of $58.07 per ADS ...
Yahoo Finance3 天
Belite Bio, Inc (BLTE)
After hours: February 7 at 4:01:31 PM EST Loading Chart for BLTE ...